WO2024150073 - METHODS FOR TREATING PRIMARY SJOGREN'S SYNDROME USING FCRN ANTAGONISTS
National phase entry:
Publication Number
WO/2024/150073
Publication Date
18.07.2024
International Application No.
PCT/IB2024/000041
International Filing Date
12.01.2024
Title **
[English]
METHODS FOR TREATING PRIMARY SJOGREN'S SYNDROME USING FCRN ANTAGONISTS
[French]
MÉTHODES DE TRAITEMENT DU SYNDROME DE SJÖGREN PRIMAIRE À L'AIDE D'ANTAGONISTES DE FCRN
Applicants **
ARGENX BV
Inventors
VAN MIDDENDORP, Joost, Johannes
JACOBS, Julie
PAPADOPOULOU, Despoina
PEENE, Isabelle, Maria A.
ELEWAUT, Dirk
Priority Data
63/438,667
12.01.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 3574 | |
| EPO | Filing, Examination | 42649 | |
| Japan | Filing | 590 | |
| South Korea | Filing | 574 | |
| USA | Filing, Examination | 14760 |
Total:
62,147
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Provided herein are methods of treating primary Sjögren's syndrome (pSS) using an effective amount of a human neonatal Fc receptor (FcRn) antagonist. FcRn antagonists for use in the treatment of pSS and for use in the manufacture of a medicament for the treatment of pSS are also provided herein.[French]
L'invention concerne des méthodes de traitement du syndrome de Sjögren primaire (pSS) à l'aide d'une quantité efficace d'un antagoniste du récepteur Fc néonatal humain (FcRn). L'invention concerne également des antagonistes de FcRn destinés à être utilisés dans le traitement de pSS et destinés à être utilisés dans la fabrication d'un médicament pour le traitement de pSS.